Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch

TLDR

• Scienture (NASDAQ: SCNX) jumped 355% to $2.60 on October 23, 2025, after launching Arbli, the first FDA-approved liquid losartan suspension.
• The stock showed extreme volatility, dropping 25% in after-hours trading and swinging between $0.83 and $2.60 the following day.
• Arbli targets a $256 million U.S. market with 71 million annual losartan prescriptions, serving patients who cannot swallow pills.
• The company secured distribution agreements covering 100+ million patients and 2,500+ hospitals through PBM and GPO partnerships.
• Scienture eliminated all convertible debt in early October by converting $1.2 million of debentures into equity at $2.4861 per share.

---

Scienture Holdings saw its stock price explode on October 23, 2025. SCNX closed at $2.60 after jumping 355% in a single trading session.

Scienture Holdings, Inc., SCNX

The catalyst was simple. The company announced it had begun shipping Arbli, its first commercial product.

Arbli is an FDA-approved liquid suspension of losartan potassium. It represents the first ready-to-use liquid form of the popular blood pressure medication.

The product fills a gap in the market. Until now, hospitals and pharmacies had to manually compound losartan tablets into liquid form for patients who struggle to swallow pills.

Market Access Already Secured

Scienture didn’t wait to build distribution channels. The company finalized multiple agreements before the product launch.

The deals include partnerships with pharmacy benefit managers and group purchasing organizations. These contracts provide access to over 100 million covered patients.

The company also secured agreements with more than 2,500 healthcare institutions. That represents roughly 20% of U.S. hospitals and clinics.

Major wholesalers and pharmacy chains are carrying the product from day one. Long-term care facilities are also part of the distribution network.

The U.S. losartan market generates about $256 million annually. Doctors write approximately 71 million prescriptions each year for the medication.

Arbli comes in a peppermint-flavored formula at 10mg/mL concentration. It requires no compounding or refrigeration.

The product is particularly useful for pediatric and elderly patients. Both groups often have difficulty with traditional tablets.

Financial House in Order

Scienture cleaned up its balance sheet ahead of the launch. The company converted all remaining convertible debentures into equity in early October.

The conversion eliminated roughly $1.2 million in debt. It also removed interest-bearing obligations from the books.

The transaction used a conversion price of $2.4861 per share. This created dilution for existing shareholders but strengthened the company’s financial position.

Executive Chairman Shankar Hariharan said the move positions Scienture to “accelerate growth trajectory” following the Arbli rollout.

The stock didn’t maintain its October 23 gains. After-hours trading on October 24 saw the price drop to around $1.94, down 25%.

Monday’s regular session brought wild swings. SCNX traded as low as $0.83 before recovering back toward $2.60.

Wall Street coverage remains sparse. The single analyst following the stock rates it a “Sell.”

The company’s next earnings report is scheduled for November 5, 2025. This will be the first financial update since Arbli began shipping.

Scienture opened the day at $0.57 before October 16. The stock reached $2.60 just seven days later.

The post Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch appeared first on Blockonomi.